stoxline Quote Chart Rank Option Currency Glossary
ARS Pharmaceuticals, Inc. (SPRY)
4.85  0.17 (3.63%)    11-28 14:42
Open: 4.67
High: 4.886
Volume: 220,487
Pre. Close: 4.68
Low: 4.6525
Market Cap: 466(M)
Technical analysis
2023-11-28 2:21:01 PM
Short term     
Mid term     
Targets 6-month :  5.85 1-year :  6.83
Resists First :  5.01 Second :  5.85
Pivot price 4.32
Supports First :  4 Second :  3.38
MAs MA(5) :  4.74 MA(20) :  4.14
MA(100) :  5.48 MA(250) :  6.53
MACD MACD :  0.2 Signal :  0.1
%K %D K(14,3) :  85 D(3) :  83.4
RSI RSI(14): 68
52-week High :  9.64 Low :  2.54
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SPRY ] has closed below upper band by 22.9%. Bollinger Bands are 24.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.82 - 4.84 4.84 - 4.86
Low: 4.6 - 4.63 4.63 - 4.65
Close: 4.63 - 4.68 4.68 - 4.72
Company Description

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Headline News

Wed, 22 Nov 2023
2023-11-22 | NDAQ:SPRY | Press Release | ARS Pharmaceuticals Inc - Stockhouse Publishing

Thu, 09 Nov 2023
2023-11-09 | NDAQ:SPRY | Press Release | ARS Pharmaceuticals Inc - Stockhouse Publishing

Thu, 09 Nov 2023
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis - Yahoo Finance

Wed, 08 Nov 2023
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders ... - GlobeNewswire

Fri, 06 Oct 2023
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray) - Yahoo Finance

Thu, 21 Sep 2023
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 96 (M)
Held by Insiders 3.758e+007 (%)
Held by Institutions 34.7 (%)
Shares Short 5,870 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.132e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -238 %
Return on Assets (ttm) 936.6 %
Return on Equity (ttm) -31.1 %
Qtrly Rev. Growth 30000 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -62 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 6.6e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android